HKEX Stock Code: 01093English|繁體|简体

2024 Results

  • Revenue RMB29,009M, -7.8%
  • Underlying profit attributable to shareholders RMB4,683M, -25.4%
  • Reported profit attributable to shareholders RMB4,328M, -26.3%
  • Basic earnings per share (underlying profit) RMB39.90 cents, -24.5%
  • Basic earnings per share (reported) RMB36.87 cents, -25.5%

Financial Reports

2024 Annual Report

Highlight - 2024 Results

Revenue
RMB29,009M, -7.8%
Underlying profit attributable to shareholders
RMB4,683M, -25.4%
Reported profit attributable to shareholders
RMB4,328M, -26.3%
Basic earnings per share (reported)
RMB39.90 cents, -24.5%
Basic earnings per share (underlying profit)
RMB36.87 cents, -25.5%

Corporate Governance

Corporate Governance

Latest News

Apr
30
VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL ...
Apr
28
NOTIFICATION LETTER TO NON-REGISTERED HOLDER AND REQUEST FORM
Apr
28
NOTIFICATION LETTER TO SHAREHOLDER AND CHANGE REQUEST FORM

Financial Calendar

Mar
28
2024 Annual Results Announcement
Mar
28
Board Meeting
* Subject to change.
>> more

Financial Reports

Financial Reports

Financial Summary

Financial Summary

IR Contacts

Address : Suite 3206, 32/F, Central Plaza,
18 Harbour Road, Wanchai, Hong Kong
Tel : (852) 2500 3144
Fax : (852) 2802 4552
E-mail : ir@cspc.hk
© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer